InDex Pharmaceuticals Holding AB stock analysis
Want to see SE:FLERIE full AI Analyst Report?
InDex Pharmaceuticals Holding AB (FLERIE) Stock Price & Analysis
FLERIE Stock Chart & Stats
- Day’s Range
- SEK 12.45 - SEK 13.10
- 52-Week Range
- SEK 12.30 - SEK 34.21
- Previous Close
- SEK 13.00
- Volume
- N/A
- Average Volume (3M)
- 79.20K
- Market Cap
- SEK 1.18B
- Enterprise Value
- SEK 1.15B
- Total Cash (Recent Filing)
- SEK 265.10M
- Total Debt (Recent Filing)
- SEK 1.60M
- Price to Earnings (P/E)
- ―
- Beta
- 0.04
- Next Earnings
- Jan 20, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Exceptionally Low Leverage
Minimal debt materially reduces interest and refinancing pressure, giving InDex greater financial flexibility than a highly leveraged biotech. This balance-sheet strength can help preserve strategic options and support continued clinical or partnering activity despite current losses.
Substantial Asset And Equity Base
The company retains a substantial reported asset and equity base relative to its very low debt burden. Although those resources are not currently producing positive returns, they provide a stronger financial foundation for executing development plans and negotiating future strategic transactions.
Focused Immunology Pipeline And Partnering Model
A focused therapeutic strategy around immunology and a lead ulcerative-colitis candidate gives the company a clear development and partnering proposition. Upfront, milestone, research funding, or royalty opportunities could provide scalable monetization if clinical and regulatory progress is achieved.
Bears Say
Persistent Cash Burn
Ongoing negative operating and free cash flow means the business is consuming cash rather than funding itself. If this pattern continues, InDex will need successful partnering, additional financing, or other capital sources to sustain clinical development and operations.
Severe And Volatile Profitability
Extremely large losses and unstable revenue demonstrate that InDex has not yet established a dependable earnings engine. This weak operating profile limits internal reinvestment capacity and makes future financial performance highly dependent on development and commercialization outcomes.
Dependence On Clinical And Partnering Success
The company’s revenue model relies on securing suitable partners and reaching clinical, regulatory, and commercialization milestones before recurring product economics can emerge. Delays or unsuccessful development outcomes could therefore postpone or reduce upfront, milestone, and royalty income.
FLERIE FAQ
What was InDex Pharmaceuticals Holding AB’s price range in the past 12 months?
What is InDex Pharmaceuticals Holding AB’s market cap?
When is InDex Pharmaceuticals Holding AB’s upcoming earnings report date?
How were InDex Pharmaceuticals Holding AB’s earnings last quarter?
Is InDex Pharmaceuticals Holding AB overvalued?
Does InDex Pharmaceuticals Holding AB pay dividends?
What is InDex Pharmaceuticals Holding AB’s EPS estimate?
How many shares outstanding does InDex Pharmaceuticals Holding AB have?
What happened to InDex Pharmaceuticals Holding AB’s price movement after its last earnings report?
Which hedge fund is a major shareholder of InDex Pharmaceuticals Holding AB?
What is the TipRanks Smart Score and how is it calculated?
Company Description
InDex Pharmaceuticals Holding AB
Flerie AB (publ) functions as a venture capital entity, concentrating its investments on nascent businesses. The firm actively seeks to fund biotechnology and pharmaceutical companies dedicated to advancing drug discovery and development, or producing innovative tools and applications aimed at addressing pressing global health concerns. Geographically, their investment scope includes Europe, the United States, and Israel. Founded in 2011, Flerie AB (publ) is headquartered in Stockholm, Sweden, and also operates a branch office in London, United Kingdom.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Ted Fjallman
- Employees
- 8
- Website
- www.flerie.com
- Address
- Skeppsbron 16, Stockholm, AB, 111 30, SE
InDex Pharmaceuticals Holding AB (FLERIE) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 4 | 13 |
| Technical Analysis | 2 | 4 | 4 |
| Moving Averages | 3 | 0 | 9 |

